

Notes to Editors:

Glossary

ACR scores: the widely accepted composite scale of improvement in RA, developed by the American College of Rheumatology (ACR). The number refers to the percentage improvement in swollen joint count, tender joint count and three or more of the following measures: patient's own assessment of disease activity; physician assessment of disease activity; patient's own assessment of RA pain; acute-phase reactant (ESR, CRP) and disability questionnaire.

DAS or Disease Activity Score: is a composite measure which is used to assess disease activity in patients with RA. DAS28 (CRP) incorporates the measurement of the number of tender and swollen joints, C-reactive protein and patient global assessment.

Current treatment regime for patients with RA

Small molecule Disease Modifying Anti-Rheumatic Drugs or DMARDs are typically used in the early treatment of RA to slow down the progression of the disease. Methotrexate is currently the most commonly prescribed DMARD. However, treatment is often discontinued for reasons of limited efficacy or side effects. For more severe or advanced conditions, the newer biological DMARDs may be used, but only as a second or third line treatment due to their high cost, currently in excess of \$10,000 per patient per year, and potential side effects. Side effects from DMARDs include increased susceptibility to infection, hair loss, the suppression of blood cell formation in bone marrow, kidney or liver damage.

About Sosei

Sosei Co. Ltd., founded in 1990 by Shinichi Tamura, the former CEO of Genentech Japan, is a leading Japanese biopharmaceutical company with significant expertise in drug development. It enriches its core product pipeline by in-licensing compounds from Western and Japanese companies, by its distinctive Drug Reprofilling Platform® (DRP®) and through new molecular entity (NME) research programmes in collaboration with biopharmaceutical companies and universities both in Japan and the West.

Sosei is also developing its own sales and marketing organization in Japan. The company is capitalising on its extensive global network established over the past 10 years in its successful technology transfer business.

About Arakis

Arakis is a UK based biopharmaceutical company that discovers, develops and commercialises innovative medicinal products based on established drugs and drug templates. Its main therapeutic areas are inflammatory disease and pain.

Arakis has four products in clinical development: AD 237 for chronic obstructive pulmonary disease (COPD) and AD 452 for rheumatoid arthritis (RA) which have completed Phase IIa trials and AD 337 for fibromyalgia syndrome and AD 923 for cancer breakthrough pain (CBP) which are in Phase I. In addition, there is a preclinical pipeline of other opportunities, two exploratory developments and a number of research projects.

Sosei acquired Arakis in August 2005.